|
Renovascular safety of sunitinib in prostate cancer: The prognostic value of hypertension and proteinuria. |
|
|
Research Funding - Amgen; Bayer Schering Pharma; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Fresenius Biotech; Gilead Sciences; Ipsen; Janssen-Cilag; LEO Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Isabelle Laure Ray-Coquard |
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - MSD; Roche Pharma AG |
Travel, Accommodations, Expenses - MSD; PharmaMar; Roche Pharma AG |
|
|
Honoraria - AstraZeneca; Bayer Schering Pharma |
Consulting or Advisory Role - Bayer Schering Pharma |
Research Funding - Bayer Schering Pharma |
|
|
Research Funding - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Archimedes; Baxter; Boehringer Ingelheim; Braun Travacare; Bristol-Myers Squibb; Fresenius Biotech; Helsinn Therapeutics; Idis Pharma; LEO Pharma; Merck; Merck Serono; Mundipharma; Pfizer; Roche Pharma AG; Sandoz |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Novartis; Pfizer; Sanofi |